Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer

The com­bi­na­tion of Roche’s check­point in­hibitor Tecen­triq and Ex­elix­is’ ki­nase in­hibitor Cabome­tyx staved off dis­ease pro­gres­sion of ad­vanced prostate can­cer for longer than a sec­ond hor­mone ther­a­py in a late-stage clin­i­cal tri­al.

The Phase III CON­TACT-02 study looked at metasta­t­ic prostate can­cer pa­tients who al­ready tried one hor­mone ther­a­py, and gave them ei­ther Roche and Ex­elix­is’ treat­ment or an­oth­er hor­mone ther­a­py. The com­bo can­cer reg­i­men ex­tend­ed me­di­an pro­gres­sion-free sur­vival by about two months com­pared to Zyti­ga or Xtan­di, ac­cord­ing to de­tailed da­ta shared at the AS­CO Gen­i­touri­nary Can­cers Sym­po­sium.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.